SAN FRANCISCO--(BUSINESS WIRE)--Osmind, the public benefit corporation helping clinicians and researchers advance new life-saving mental health treatments, today announced a $40 million Series B ...

San Francisco-based Osmind announced today that its electronic health record system for mental health clinicians has integrated Zoom virtual visits within its technology platform as part of the ...

SAN FRANCISCO--(BUSINESS WIRE)--Osmind, a healthcare technology company building the first digital infrastructure for neuropsychiatry, closed $15 million in Series A funding to further develop and ...

Tasman Therapeutics today announced a multi-year strategic partnership with Osmind, the market leader in technology and real-world evidence for psychiatry, to support its R-107 Ketamine program. The ...

Osmind presented a retrospective comparative study of de-identified electronic health record data in a sample of 8,224 patients with treatment resistant depression treated with IV ketamine and 1,830 ...

US digital health firm Osmind – which had developed an electronic health record (EHR) system for patients with mental illness – has added to its finances with a $40 million Series B financing. The San ...

This article was originally published on Microdose Psychedelic Insights and appears here with permission. This week’s Psychedelic Guide is Lucia Huang, Co-founder and CEO of Osmind. Osmind is ...

Jimmy Qian and Lucia Huang, the co-founders of Osmind, a new clinical practice management and data analysis platform for mental health providers focusing on cutting edge psychedelic treatments, met at ...

Osmind, a Mountain View company that provides clinical practice management and data analysis software to mental health providers, pitched last month at Y Combinator Demo Days. Shown here are ...

Funding will support expansion of Osmind’s next-generation neuropsychiatry software platform and team growth SAN FRANCISCO–(BUSINESS WIRE)–July 1, 2021– Osmind, a healthcare technology company ...

Tasman Therapeutics enters partnership with Osmind to advance R-107 for depressive disorders: San Francisco Thursday, August 13, 2026, 17:00 Hrs [IST] Tasman Therapeutics, a clini ...